title: The value of an acute octreotide suppression test in predicting response to long-term somatostatin analogue therapy in patients with acromegaly.
abstract: BACKGROUND
  The usefulness of the acute octreotide test in the selection of patients with acromegaly for chronic somatostatin depot analogues treatment is controversial.
  
  
  OBJECTIVE
  To determine the efficacy of acute octreotide suppression test (OST) in predicting response to long-term somatostatin analogue (Octreotide-long-acting repeatable, OCT-LAR) therapy in patients with acromegaly.
  
  
  METHODS
  Prospective study (2006-2007) conducted at a tertiary healthcare centre in western India.
  
  
  METHODS
  Sixteen drug-naive patients with active acromegaly (postoperative+/-post radiotherapy) underwent 50 microg subcutaneous OST. Ten patients were treated with OCT-LAR for one year. Remission was defined as a nadir growth hormone (GH) < 1 ng/ml during 75 g oral glucose tolerance test (OGTT) (0, 10, 30, 60, 120, 180 min) and normal age, sex-matched insulin-like growth factor 1 (IGF1) levels.
  
  
  METHODS
  SPSS Software Version 11 was used for data analysis.
  
  
  RESULTS
  Using GH cutoff.
  
  
  CONCLUSIONS
  Nadir GH < 1 ng/ml following an OST is a useful predictive marker of achieving disease remission with long-term OCT-LAR therapy.
authors.affiliation: Department of Endocrinology, Seth G.S. Medical College and K.E.M. Hospital, Mumbai, India.
authors.forename: T R
authors.initials: TR
authors.lastname: Bandgar
authors.forename: V
authors.initials: V
authors.lastname: Sarathi
authors.forename: V
authors.initials: V
authors.lastname: Shivane
authors.forename: N
authors.initials: N
authors.lastname: Bansode
authors.forename: P S
authors.initials: PS
authors.lastname: Menon
authors.forename: N S
authors.initials: NS
authors.lastname: Shah
mesh_terms: D000172:Acromegaly / Q000097:blood / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D005260:Female; D019382:Human Growth Hormone / Q000097:blood / Q000378:metabolism; D006801:Humans; D007194:India; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use; D018579:Patient Selection; D011237:Predictive Value of Tests; D011379:Prognosis; D011446:Prospective Studies; D012680:Sensitivity and Specificity; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D019382:Human Growth Hormone; D013004:Somatostatin; D007334:Insulin-Like Growth Factor I; D015282:Octreotide